COMMUNIQUÉS West-GlobeNewswire
-
Olympia Pharmaceuticals Launches Rebranded Website, Ushering in a New Era of Seamless Navigation and Advanced Features
06/01/2026 -
Coherus Management to Present at the 44th Annual J.P. Morgan Healthcare Conference
06/01/2026 -
QHSLab (OTCQB:USAQ) Issues Unaudited Financial and Operational Update Ahead of January 2026 Investor Session
06/01/2026 -
Medtech Incubator Partners with Leap Distributors to Support U.S. Market Expansion Efforts
06/01/2026 -
SoldierStrong Announces Annual SoldierScholar Recipients For 2025
06/01/2026 -
Dewpoint Therapeutics Launches Initiative to Build Viral Condensate Phenomics Atlas for HPV
06/01/2026 -
LQpay Launches Agentic AI API, Delivering Human-Like Access Across 125+ EMR/PM Systems Through a Single REST API
06/01/2026 -
Apogee Therapeutics Announces Positive Interim Results from Phase 1b Trial of Zumilokibart (APG777), its Potentially Best-in-Class Anti-IL-13 Antibody, in Patients with Mild-to-Moderate Asthma and Highlights 2026 Anticipated Milestones and Outlook
06/01/2026 -
Aclarion Announces First Patient Enrollments at Two Additional CLARITY Trial Sites and Provides Guidance on Expected Availability of Initial Data
06/01/2026 -
Biosplice Announces the Submission of its New Drug Application (NDA) to the FDA for Lorecivivint (LOR) to Treat Knee Osteoarthritis
06/01/2026 -
Johnson & Johnson submits application to the European Medicines Agency for TECVAYLI®▼ (teclistamab) in combination with DARZALEX® (daratumumab) subcutaneous formulation for patients with relapsed/refractory multiple myeloma
06/01/2026 -
Aclaris Therapeutics Announces Positive Interim Results of Phase 1a Trial of Anti-TSLP/IL-4Rα Bispecific Antibody ATI-052 Supporting Expedited Clinical Development
06/01/2026 -
Fractyl Health Appoints Lara Smith Weber as Chief Financial Officer to Support Commercial-Stage Preparedness
06/01/2026 -
Kymera Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13
06/01/2026 -
Gain Therapeutics Highlights Biomarker Evidence Supporting Disease-Modifying Potential of GT-02287
06/01/2026 -
Abpro and Celltrion, Inc. Announce U.S. FDA IND Clearance for Lead Multispecific Antibody Cancer Candidate ABP-102 / CT-P72
06/01/2026 -
Alumis’ Envudeucitinib Delivers Leading Skin Clearance Among Next-Generation Oral Plaque Psoriasis Therapies in Phase 3 Program
06/01/2026 -
Fortrea to Present at Upcoming J.P. Morgan Healthcare Conference
06/01/2026 -
Alesta to Highlight ALE1 Clinical Progress at 44th Annual JP Morgan Healthcare Conference
06/01/2026
Pages